Toll Free: 1-888-928-9744

Plexxikon Inc. - Product Pipeline Review - 2014

Published: Oct, 2014 | Pages: 37 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Plexxikon Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Plexxikon Inc. - Product Pipeline Review - 2014', provides an overview of the Plexxikon Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Plexxikon Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Plexxikon Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Plexxikon Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Plexxikon Inc.'s pipeline products

Reasons to buy

- Evaluate Plexxikon Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Plexxikon Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Plexxikon Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Plexxikon Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Plexxikon Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Plexxikon Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Plexxikon Inc. Snapshot 5
Plexxikon Inc. Overview 5
Key Information 5
Key Facts 5
Plexxikon Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Plexxikon Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Out-Licensed Products 11
Out-Licensed Products/Combination Treatment Modalities 12
Plexxikon Inc. - Pipeline Products Glance 13
Plexxikon Inc. - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
Plexxikon Inc. - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Plexxikon Inc. - Drug Profiles 16
PLX-3397 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
PLX-3603 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
PLX-5622 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
PLX-7486 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Small Molecule to Target Nuclear Receptor for Obesity 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Small Molecules to Agonize PPAR for Multiple Sclerosis 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Small Molecules to Inhibit FMS Kinase for Alzheimer Disease 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Small Molecules to Inhibit Raf Kinase for Polycystic Kidney Disease 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Plexxikon Inc. - Pipeline Analysis 26
Plexxikon Inc. - Pipeline Products by Target 26
Plexxikon Inc. - Pipeline Products by Route of Administration 27
Plexxikon Inc. - Pipeline Products by Molecule Type 28
Plexxikon Inc. - Pipeline Products by Mechanism of Action 29
Plexxikon Inc. - Recent Pipeline Updates 30
Plexxikon Inc. - Dormant Projects 33
Plexxikon Inc. - Discontinued Pipeline Products 34
Discontinued Pipeline Product Profiles 34
PLX-3397 34
Plexxikon Inc. - Locations And Subsidiaries 35
Head Office 35
Appendix 36
Methodology 36
Coverage 36
Secondary Research 36
Primary Research 36
Expert Panel Validation 36
Contact Us 37
Disclaimer 37
List of Tables
Plexxikon Inc., Key Information 5
Plexxikon Inc., Key Facts 5
Plexxikon Inc. - Pipeline by Indication, 2014 8
Plexxikon Inc. - Pipeline by Stage of Development, 2014 9
Plexxikon Inc. - Monotherapy Products in Pipeline, 2014 10
Plexxikon Inc. - Out-Licensed Products in Pipeline, 2014 11
Plexxikon Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014 12
Plexxikon Inc. - Phase II, 2014 13
Plexxikon Inc. - Phase I, 2014 14
Plexxikon Inc. - Preclinical, 2014 15
Plexxikon Inc. - Pipeline by Target, 2014 26
Plexxikon Inc. - Pipeline by Route of Administration, 2014 27
Plexxikon Inc. - Pipeline by Molecule Type, 2014 28
Plexxikon Inc. - Pipeline Products by Mechanism of Action, 2014 29
Plexxikon Inc. - Recent Pipeline Updates, 2014 30
Plexxikon Inc. - Dormant Developmental Projects,2014 33
Plexxikon Inc. - Discontinued Pipeline Products, 2014 34 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify